The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Background Reference intervals of thyroid-stimulating hormone (TSH) and free thyroxine (FT 4 ) are statistically defined by the 2·5–97·5th percentiles, without accounting for potential risk of clinical outcomes. We aimed to define the optimal healthy ranges of TSH and FT 4 based on the risk of cardiovascular disease and mortality. Methods This systematic review and individual participant data (IPD) meta-analysis identified eligible prospective cohorts through the Thyroid Studies Collaboration, supplemented with a systematic search via Embase, MEDLINE (Ovid), Web of science, the Cochrane Central Register of Controlled Trials, and Google Scholar from Jan 1, 2011, to Feb 12, 2017 with an updated search to Oct 13, 2022 (cohorts found in the second search were not included in the IPD). We included cohorts that collected TSH or FT 4 , and cardiovascular outcomes or mortality for adults (aged ≥18 years). We excluded cohorts that included solely pregnant women, individuals with overt thyroid diseases, and individuals with cardiovascular disease. We contacted the study investigators of eligible cohorts to provide IPD on demographics, TSH, FT 4 , thyroid peroxidase antibodies, history of cardiovascular disease and risk factors, medication use, cardiovascular disease events, cardiovascular disease mortality, and all-cause mortality. The primary outcome was a composite outcome including cardiovascular disease events (coronary heart disease, stroke, and heart failure) and all-cause mortality. Secondary outcomes were the separate assessment of cardiovascular disease events, all-cause mortality, and cardiovascular disease mortality. We performed one-step (cohort-stratified Cox models) and two-step (random-effects models) meta-analyses adjusting for age, sex, smoking, systolic blood pressure, diabetes, and total cholesterol. The study was registered with PROSPERO, CRD42017057576. Findings We identified 3935 studies, of which 53 cohorts fulfilled the inclusion criteria and 26 cohorts agreed to participate. We included IPD on 134 346 participants with a median age of 59 years (range 18–106) at baseline. There was a J-shaped association of FT 4 with the composite outcome and secondary outcomes, with the 20th (median 13·5 pmol/L [IQR 11·2–13·9]) to 40th percentiles (median 14·8 pmol/L [12·3–15·0]) conveying the lowest risk. Compared with the 20–40th percentiles, the age-adjusted and sex-adjusted hazard ratio (HR) for FT 4 in the 80–100th percentiles was 1·20 (95% CI 1·11–1·31) for the composite outcome, 1·34 (1·20–1·49) for all-cause mortality, 1·57 (1·31–1·89) for cardiovascular disease mortality, and 1·22 (1·11–1·33) for cardiovascular disease events. In individuals aged 70 years and older, the 10-year absolute risk of composite outcome increased over 5% for women with FT 4 greater than the 85th percentile (median 17·6 pmol/L [IQR 15·0–18·3]), and men with FT 4 greater than the 75th percentile (16·7 pmol/L [14·0–17·4]). Non-linear associations were identified for TSH, with the 60th (median 1·90 mIU/L [IQR 1·68–2·25]) to 80th percentiles (2·90 mIU/L [2·41–3·32]) associated with the lowest risk of cardiovascular disease and mortality. Compared with the 60–80th percentiles, the age-adjusted and sex-adjusted HR of TSH in the 0–20th percentiles was 1·07 (95% CI 1·02–1·12) for the composite outcome, 1·09 (1·05–1·14) for all-cause mortality, and 1·07 (0·99–1·16) for cardiovascular disease mortality. Interpretation There was a J-shaped association of FT 4 with cardiovascular disease and mortality. Low concentrations of TSH were associated with a higher risk of all-cause mortality and cardiovascular disease mortality. The 20–40th percentiles of FT 4 and the 60–80th percentiles of TSH could represent the optimal healthy ranges of thyroid function based on the risk of cardiovascular disease and mortality, with more than 5% increase of 10-year composite risk identified for FT 4 greater than the 85th percentile in women and men older than 70 years. We propose a feasible approach to establish the optimal healthy ranges of thyroid function, allowing for better identification of individuals with a higher risk of thyroid-related outcomes. Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“another metaanalysis identified that the 20-40th percentiles of FT4 and the 60-80th percentiles of TSH were the optimal ranges of thyroid function, based on having lower risk of cardiovascular disease and mortality.137”
From Hypothyroidism (2024) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management
Surks, M. I., Ortiz, E., Daniels, G. H., Sawin, C. T., Col, N. F., Cobin, R. H., Franklyn, J. A., Hershman, J. M., Burman, K. D., Denke, M. A., et al. (2004) · JAMA · doi:10.1001/jama.291.2.228 · Cited by 1,800
Meta-analysis of individual participant data: rationale, conduct, and reporting
Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010) · BMJ · doi:10.1136/bmj.c221 · Cited by 1,701
Hernán, M. A. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181c1ea43 · Cited by 1,370
Subclinical Hypothyroidism and the Risk of Coronary Heart Disease and Mortality
Rodondi, N., den Elzen, W. P. J., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., Åsvold, B. O., Iervasi, G., Imaizumi, M., Collet, T.-H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1361 · Cited by 1,216
Self-citationWillett, W. C., Dietz, W. H., & Colditz, G. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410607 · Cited by 1,143
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Cited by
The Rotterdam Study. Design update and major findings between 2020 and 2024
Ikram, M. A., Kieboom, B. C. T., Brouwer, W. P., Brusselle, G., Chaker, L., Ghanbari, M., Goedegebure, A., Ikram, M. K., Kavousi, M., de Knegt, R. J., et al. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-023-01094-1 · Cited by 156
“…also a leading cohort in both the Thyroid Studies Collaboration [48] and the ThyroidOmics Consortium [49], where in the former we have recently described the optimal healthy ranges of thyroid function based on cardiovascular disease risk using data on over 130,000 participants from 26 cohorts [50].”
Self-citationTaylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Self-citationMetabolic Syndrome, Thyroid Dysfunction, and Cardiovascular Risk: The Triptych of Evil
Pingitore, A., Gaggini, M., Mastorci, F., Sabatino, L., Cordiviola, L., & Vassalle, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910628 · Cited by 47
“In a recent study, TH metabolic abnormalities increased CV risk in the general population [26].”
BackgroundSelf-citationHypothyroidism, atherosclerosis and cardiovascular risk prevention
Duntas, L. H., & Feldt‐Rasmussen, U. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01202-z · Cited by 26
Metabolic and Functional Cross Talk Between the Thyroid and Liver
Chng, C. L., Goh, G. B., & Yen, P. M. (2025) · Thyroid · doi:10.1089/thy.2025.0178 · Cited by 37
Metadata
- Authors
- Xu, Y., Derakhshan, A., Hysaj, O., Wildisen, L., Ittermann, T., Pingitore, A., Abolhassani, N., Medici, M., Kiemeney, L. A. L. M., Riksen, N. P., Dullaart, R. P. F., Trompet, S., Dörr, M., Brown, S. J., Schmidt, B., Führer-Sakel, D., Vanderpump, M. P. J., Muendlein, A., Drexel, H., Fink, H. A., Ikram, M. K., Kavousi, M., Rhee, C. M., Bensenor, I. M., Azizi, F., Hankey, G. J., Iacoviello, M., Imaizumi, M., Ceresini, G., Ferrucci, L., Sgarbi, J. A., Bauer, D. C., Wareham, N., Boelaert, K., Bakker, S. J. L., Jukema, J. W., Vaes, B., Iervasi, G., Yeap, B. B., Westendorp, R. G. J., Korevaar, T. I. M., Völzke, H., Razvi, S., Gussekloo, J., Walsh, J. P., Cappola, A. R., Rodondi, N., Peeters, R. P., & Chaker, L.
- Affiliations
- Erasmus MC (NL)
- University of Bern (CH)
- Universitätsmedizin Greifswald (DE)
- Istituto di Fisiologia Clinica (IT)
- Radboud University Nijmegen (NL)
- Radboud University Medical Center (NL)
- University Medical Center Groningen (NL)
- Leiden University Medical Center (NL)
- Sir Charles Gairdner Hospital (AU)
- University of Duisburg-Essen (DE)
- Vorarlberg Institute for Vascular Investigation and Treatment (AT)
- Private University in the Principality of Liechtenstein (LI)
- University of Minnesota (US)
- University of California, Irvine (US)
- Research Institute for Endocrine Sciences (IR)
- The University of Western Australia (AU)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Radiation Effects Research Foundation (JP)
- Ospedale di Parma (IT)
- National Institute on Aging (US)
- Faculdade de Medicina de Marília (BR)
- University of California, San Francisco (US)
- University of Birmingham (GB)
- KU Leuven (BE)
- University of Copenhagen (DK)
- Newcastle University (GB)
- University of Pennsylvania (US)
- Corresponding author
- Chaker, Layal
- ORCID
- Xu, Yanning
- Derakhshan, Arash
- Hysaj, Ola
- Wildisen, Lea
- Ittermann, Till
- Pingitore, Alessandro
- Abolhassani, Nazanin
- Medici, Marco
- Kiemeney, Lambertus A L M
- Riksen, Niels P
- Dullaart, Robin P F
- Trompet, Stella
- Dörr, Marcus
- Brown, Suzanne J
- Schmidt, Börge
- Muendlein, Axel
- Drexel, Heinz
- Fink, Howard A
- Kavousi, Maryam
- Rhee, Connie M
- Azizi, Fereidoun
- Hankey, Graeme J
- Iacoviello, Massimo
- Ceresini, Graziano
- Ferrucci, Luigi
- Sgarbi, José A
- Bauer, Douglas C
- Boelaert, Kristien
- Bakker, Stephan J L
- Jukema, J Wouter
- Vaes, Bert
- Iervasi, Giorgio
- Yeap, Bu B
- Westendorp, Rudi G J
- Korevaar, Tim I M
- Völzke, Henry
- Razvi, Salman
- Gussekloo, Jacobijn
- Walsh, John P
- Cappola, Anne R
- Rodondi, Nicolas
- Peeters, Robin P
- Chaker, Layal
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 11
- Issue
- 10
- Pages
- 743-754
- ISSN
- 2213-8587 (ISSN-L)
- PMC
- PMC10866328
- OpenAlex
- W4386553499
- Cited by
- 61
- References
- 69
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 15 · 2023: 5
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Apollo
- Open Access CRIS of the University of Bern
- Funders
- National Science Foundation
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Edwards Lifesciences
- Boston Scientific Corporation
- Merck KGaA
- Amarin Corporation
- Cancer Research UK (C864/A14136)
- Deutsche Forschungsgemeinschaft (JO-170/8-1, SI 236/8–1, 236/8-1, SFB/TR 296, HO 3314/2-1, ER 155/6-1, EI 969/2-3, INST 58219/32-1, PE 2309/2-1, KN885/3-1)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (200606)
- Bundesministerium für Bildung und Forschung (01EG0401, 01ER1001D, 01GS0820_WB2-C, 01GI0860, 01GI0856, 01GI0205)
- Novo Nordisk (NNF17OC0027812)
- Novo Nordisk Fonden (NNF17OC0027812)
- Heinz Nixdorf Stiftung (SI 236/8-1, ER 155/6-1)
- Spinnaker Health Research Foundation
- National Institutes of Health (N01-AG-6-2103, n01hc085082-026, n01hc085081-021, HHSN268201800001C, n01hc085079-024, n01hc085083-027, n01hc085080-026, N01‐AG‐6‐2106, n01hc085086-022, HHSN268200800007C, N01-AG-6-2101, 75N92021D00006, Z99 AG999999, HHSN268201200036C, n01hc055222-001, N01HC85086, N01-HC-85082, N01HC85079, N01HC85080, N01HC85083, N01-HC-85081, UL1TR002369)
- Medical Research Council (MC_UU_12015/1, C864/A14136, MR/N003284/1, MC_UU_00006/1))
- National Health and Medical Research Council
- Netherlands Heart Institute
- National Institute on Aging (N01‐AG‐6–2101, R01‐NR012459, N01HC85081, N01HC85079, U01AG042145, N01-HC-85080, N01-HC-85082, R01AG066671, U01AG042168, R01AG028050, R01AG032317, AG042140, N01HC55222, HHSN268200800007C, AG042139, U01AG042143, R01AG027012, AG042168, U01AG027810, AG042124, N01-HC-85083, AG042145, 75N92021D00006, U01AG042139, N01AG62106, U01AG042124, K24AG042765, AG027810, U01AG042140, N01‐HC‐85086, R01AG023629, AG042143, HHSN268201800001C, N01-AG-62103, HHSN268201200036C)
- National Heart, Lung, and Blood Institute (N01-HC-85081, N01 HC085086, N01HC-85083, 75N 92021D00006, R01-NR012459, N01 HC085079, N01 HC085083, N01HC85082, N01 HC85086, N01 HC085080, HHSN 268200800007C, HHSN268201800001C, N01HC85080, U01HL130114, N01AG62101, N01 HC55222, N01AG62106, HHSN268201200036C, N01HC085082, U01HL080295, N01 HC055222, N01AG62103, N01 HC085081, N01-HC85079)
- National Institute of Nursing Research (N01-AG-6–2101, N01-AG-6-2103, N01-AG-6–2106, R01NR012459)
- National Institute of Neurological Disorders and Stroke (N01-AG-6-2106, N01-AG-6-2103, R01-NR012459, HHSN268200800007C, N01-HC-85080, N01-HC-85083, HHSN268201800001C, N01HC85082, 75N92021D00006, N01-AG-6-2101, N01-HC-85081, R01-AG028050, N01-HC-85086, N01 HC-55222, N01HC85079, HHSN268201200036C)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01AR066160, AR066160)
- National Center for Advancing Translational Sciences (TR002369)
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- thyroid-stimulating hormone, free thyroxine, cardiovascular disease, all-cause mortality, cardiovascular mortality, J-shaped association, thyroid peroxidase antibodies, thyroid autoimmunity, coronary artery disease, stroke, heart failure
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Female, Humans, Male, Middle Aged, Pregnancy, Prospective Studies, Thyroid Function Tests, Thyroid Gland, Thyrotropin, Thyroxine, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis. https://app.cochat.ai/papers/10.1016/s2213-8587(23)00227-9
- The paper
- Xu, Y., Derakhshan, A., Hysaj, O., Wildisen, L., Ittermann, T., Pingitore, A., Abolhassani, N., Medici, M., Kiemeney, L. A. L. M., Riksen, N. P., Dullaart, R. P. F., Trompet, S., Dörr, M., Brown, S. J., Schmidt, B., Führer-Sakel, D., Vanderpump, M. P. J., Muendlein, A., Drexel, H., . . . Chaker, L. (2023). The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(23)00227-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.